We have identified long-incubation viral agents that share epitopes with hepatitis B virus (HBV). During chimpanzee infectivity studies, these agents may be recognized in the liver since they possess complementary nucleic acid sequences with HBV DNA; the genomic size was found to be 3.2 kilobases, identical to that of HBV. Liver injury was produced and there was antigen expression in hepatocytes. Chimpanzees were not protected by prior immunization with hepatitis B surface antigen; conversely, they were still susceptible to HBV after recovery from infection with such agents. These findings suggest that these hepatitis B virus-related variants appear to be immunologically distinct from HBV.
Previous studies on sera using monoclonal anti-hepatitis B surface antigen antibody (anti-HBsAg) radioimmunoassays (M-RIAs) have established that there are individuals with acute and chronic hepatitis infection and hepatocellular carcinoma whose serum demonstrates positive binding activity only in these tests (1) (2) (3) (4) (5) (6) (7) (8) . Such patients were found to be negative for hepatitis B surface antigen (HBsAg) by polyclonal anti-HBsAg RIA (P-RIA) and some lacked evidence of recent or past exposure to hepatitis B virus (HBV) as shown by the absence of antibodies to the core (antiHBcAg) and to surface antigens (anti-HBsAg) in the blood (4) (5) (6) (7) (8) . HBV DNA hybridizable sequences were detected in the liver and serum ofa significant number of such individuals and this finding correlated with the detection of antigen in serum by M-RIAs (4, 6) . However, very little is known regarding the biologic properties and characteristics of the M-RIA HBV DNA-positive agents in serum. We report here the identification, transmission, and partial characterization of some viral agents during chimpanzee infectivity studies. These hepatitis viral variants appear to be antigenically related to and share nucleic acid homology with HBV.
METHODS
Sera from two individuals, designated G and M, were selected for inoculation into four chimpanzees. Patient G is a 44-year-old alcoholic with no clinical evidence of liver disease. HBsAg was undetectable by P-RIA but his serum was positive for anti-HBsAg and anti-HBcAg antibodies [AUSAB and CORAB, respectively (Abbott)]. The M-RIA measured binding activity at a S/N ratio of 3.51 (normal, <2.1), defined as the mean cpm of the patient G serum divided by the mean cpm of the negative control serum. Dot blot hybridization analysis with a 32P-labeled HBV DNA probe revealed a weakly positive signal in the serum. Patient M was a 38-year-old with primary hepatocellular carcinoma.
His serum was negative for HBsAg, anti-HBsAg and antiHBcAg antibodies by P-RIAs but was found to be reactive at a S/N ratio of 24.0 by M-RIA, and HBV DNA complementary sequences were detected by dot blot analysis.
Two chimpanzees (Dolf and lanthe) were previously immunized with a yeast recombinant HBV DNA-derived HBsAg vaccine. These chimpanzees had been subsequently challenged with a standard National Institutes ofHealth HBV inoculum known to produce infection in unimmunized chimpanzees; both animals were found to be protected from HBV infection. The details of these experiments have been reported elsewhere (9) . Two other chimpanzees (Sjef and Jimmie) had not been previously exposed to HBV or to the non-A, non-B hepatitis agents, and their serum was negative for HBsAg, anti-HBsAg, and anti-HBcAg antibodies. In contrast, Dolf and Ianthe had high titer anti-HBsAg antibodies as the result of past vaccination with HBsAg; anti-HBcAg antibodies, however, were not present. lanthe and Sjef were inoculated intravenously with 3 ml of serum M, and Jimmie and Dolf were inoculated with 3 ml of serum G. After injection of serum, the chimpanzees were serially bled for measurement of alanine aminotransferase values, HBsAg, anti-HBsAg, and anti-HBcAg titers, and M-RIAs and HBV DNA hybridization studies. In addition, serial liver biopsies were performed for HBV DNA hybridization analysis as well as for immunoperoxidase staining of hepatocytes for antigen expression using a monoclonal anti-HBsAg antibody.
Details of the immunization protocols, cell fusion techniques, and growth and cloning of the hybridomas producing anti-HBsAg antibodies have been reported (10) . Monoclonal antibodies designated 5D3, 5C3, and 5Cil (IgM, IgG2., and IgG1, respectively) were selected from a library of monoclonal antibodies for use in the M-RIAs since they recognize all known subtypes or viral strains of HBV (11) , distinguish separate and distinct determinants on HBsAg (3), and possess high-affinity constants for epitopes on the viral protein (10) . A multiple-site "simultaneous sandwich" RIA using all three antibodies for measurement of HBsAg-associated epitopes in serum including the sensitivity and specificity of the assay has been reported (7, 8) . In addition, we performed single HBsAg-associated determinant analysis with the MRIAs where, for example, 5D3 was linked to the solid-phase support and also served as the "25I-labeled tracer antibody, as well as using 5Cil and 5C3 separately as the radiolabeled indicator antibodies.
The spot test 32P-labeled HBV DNA hybridization studies were performed on 200 jLd of serum as described elsewhere (6, 12 kilobases (kb), a size identical to the HBV genome (14) . In addition, there was low-level antigen expression on the plasma membrane and in the cytoplasm of hepatocytes at day 120 but not at day 50, as shown by the immunoperoxidase staining reaction with monoclonal antibody 5C3 (Fig. 4) . The other chimpanzee (Jimmie) exhibited an incubation period of 70 days; the duration of antigenemia was far longer in this animal without prior exposure to HBV, as shown in Fig. 2 . Similar to the results observed in Dolf (Fig. 1) , anti-HBcAg and anti-HBsAg antibodies did not develop during active infection and after recovery. However, Jimmie was still susceptible to HBV and developed HBsAg and anti-HBcAg antibodies during infection as measured by P-RIAs (Fig. 2) . Thus, there was no cross-protection induced by the agent present in serum G with HBV. HBV DNA-hybridizable sequences were not detected in liver biopsy specimens, and they also stained negative for antigen with monoclonal anti-HBsAg 5C3.
Figs. 5 and 6 depict the course of infection in chimpanzees lanthe and Sjef after inoculation with serum M under similar experimental conditions. Infection as defined by the detection ofantigen in the circulation occurred in the HBV immune chimpanzee (lanthe) with pre-existing high titer anti-HBsAg antibodies as well as in Sjef, not previously exposed to HBV. Similar to the previous studies with serum G, anti-HBsAg and anti-HBsAg antibodies did not develop during antigenemia or after recovery. HBV DNA complementary sequences were identified in the liver of both animals at the time of antigen detection in serum but not during the incubation period (Fig.  3) ; the genomic size of the agents transmitted by serum M also was found to be 3.2 kb. Cytoplasmic and membranous antigen expression was demonstrated in hepatocytes by immunoperoxidase staining in Ianthe, but in Sjef, hepatocytes stained negative (data not shown). 
DISCUSSION
We have demonstrated the presence of transmissible agents in M-RIA reactive HBV DNA positive serum derived from two individuals, one of whom had no recent or past exposure to HBV, as shown by the absence of HBsAg and anti-HBsAg and anti-HBcAg antibodies. The present results confirm and extend our previous observations-namely, that there are patients with acute and chronic hepatitis and hepatocellular carcinoma reactive for HBsAg-associated epitopes in serum and HBV DNA complementary sequences in liver and serum that are not detectable by conventional assays (6) . The infectious potential of such serum has now been established and we are led to believe from our experiments that these long incubation agents share epitopes and nucleic acid homology with HBV. For example, the monoclonal antibodies used in the RIAs designated 5D3, SC1l, and 5C3 distinguish a domain epitopes on HBsAg and therefore have been found to identify all known strains of HBV (11) . It is noteworthy that prior immunization with a HBV-derived recombinant HBsAg Proc. Nad. Acad. Sci. USA 83 (1986) 
